r1u37sh

Property	Value
?:abstract	BACKGROUND: African swine fever (ASF) leads to high mortality in domestic pigs and wild boar and is caused by the African swine fever virus (ASFV). Currently, no vaccine is commercially available for prevention, and the epidemic is still spreading. Here, we constructed a recombinant pseudorabies virus (PRV) (PRV-ΔgE/ΔgI/ΔTK-(CD2v)) that expresses the CD2v protein of ASFV and evaluated its effectiveness and safety as a vaccine candidate in mice. METHODS: A homologous recombination fragment containing ASFV CD2v was synthesized and co-transfected into HEK 293 T cells, a knockout vector targeting the PRV TK gene. The transfected cells were infected with PRV-ΔgE/ΔgI, and the recombinant strain (PRV-ΔgE/ΔgI/ΔTK-(CD2v)) was obtained by plaque purification in Vero cells. The expression of ASFV CD2v in the recombinant virus was confirmed by sequencing, Western blotting, and immunofluorescence analysis, and the genetic stability was tested in Vero cells over 20 passages. The virulence, immunogenicity and protective ability of the recombinant virus were further tested in a mouse model. RESULTS: The PRV-ΔgE/ΔgI/ΔTK-(CD2v) recombinant strain is stable in Vero cells, and the processing of CD2v does not depend on ASFV infection. The vaccination of PRV-ΔgE/ΔgI/ΔTK-(CD2v) causes neither pruritus, not a systemic infection and inflammation (with the high expression of interleukin-6 (IL6)). Besides, the virus vaccination can produce anti-CD2v specific antibody and activate a specific cellular immune response, and 100% protect mice from the challenge of the virulent strain (PRV-Fa). The detoxification occurs much earlier upon the recombinant virus vaccination and the amount of detoxification is much lower as well. CONCLUSIONS: The PRV-ΔgE/ΔgI/ΔTK-(CD2v) recombinant strain has strong immunogenicity, is safe and effective, and maybe a potential vaccine candidate for the prevention of ASF and Pseudorabies.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0001753> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0021368> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0033774> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0033840> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0042776> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0333463> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0560617> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C0597363> <https://research.tib.eu/covid-19/entity/4r1u37sh_hasAnnotation_C1336633>
?:creator	<https://research.tib.eu/covid-19/entity/Feng%2C_Zhihua%3B_Chen%2C_Jianghua%3B_Liang%2C_Wangwang%3B_Chen%2C_Wenzhi%3B_Li%2C_Zhaolong%3B_Chen%2C_Qi%3B_Cai%2C_Shaoli>
?:doi	<https://research.tib.eu/covid-19/entity/10.1186/s12985-020-01450-7>
?:doi	10.1186/s12985-020-01450-7
?:externalLink	<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668019/>
?:journal	Virol_J
?:license	cc-by
?:pdf_json_files	document_parses/pdf_json/933fa73f0e02d1ea42a6c6991248e9f71f6d884b.json
?:pmc_json_files	document_parses/pmc_json/PMC7668019.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7668019>
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/4r1u37sh_HAS_C0597363_INTERACTS_WITH_C0001753> <https://research.tib.eu/covid-19/entity/4r1u37sh_HAS_C2936239_INTERACTS_WITH_C1336633>
?:sha_id	<https://research.tib.eu/covid-19/entity/933fa73f0e02d1ea42a6c6991248e9f71f6d884b>
?:source	PMC
?:title	The recombinant pseudorabies virus expressing African swine fever virus CD2v protein is safe and effective in mice
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-16

Property

Value

?:abstract

BACKGROUND: African swine fever (ASF) leads to high mortality in domestic pigs and wild boar and is caused by the African swine fever virus (ASFV). Currently, no vaccine is commercially available for prevention, and the epidemic is still spreading. Here, we constructed a recombinant pseudorabies virus (PRV) (PRV-ΔgE/ΔgI/ΔTK-(CD2v)) that expresses the CD2v protein of ASFV and evaluated its effectiveness and safety as a vaccine candidate in mice. METHODS: A homologous recombination fragment containing ASFV CD2v was synthesized and co-transfected into HEK 293 T cells, a knockout vector targeting the PRV TK gene. The transfected cells were infected with PRV-ΔgE/ΔgI, and the recombinant strain (PRV-ΔgE/ΔgI/ΔTK-(CD2v)) was obtained by plaque purification in Vero cells. The expression of ASFV CD2v in the recombinant virus was confirmed by sequencing, Western blotting, and immunofluorescence analysis, and the genetic stability was tested in Vero cells over 20 passages. The virulence, immunogenicity and protective ability of the recombinant virus were further tested in a mouse model. RESULTS: The PRV-ΔgE/ΔgI/ΔTK-(CD2v) recombinant strain is stable in Vero cells, and the processing of CD2v does not depend on ASFV infection. The vaccination of PRV-ΔgE/ΔgI/ΔTK-(CD2v) causes neither pruritus, not a systemic infection and inflammation (with the high expression of interleukin-6 (IL6)). Besides, the virus vaccination can produce anti-CD2v specific antibody and activate a specific cellular immune response, and 100% protect mice from the challenge of the virulent strain (PRV-Fa). The detoxification occurs much earlier upon the recombinant virus vaccination and the amount of detoxification is much lower as well. CONCLUSIONS: The PRV-ΔgE/ΔgI/ΔTK-(CD2v) recombinant strain has strong immunogenicity, is safe and effective, and maybe a potential vaccine candidate for the prevention of ASF and Pseudorabies.

is ?:annotates of